论文部分内容阅读
目的:研究奥沙利铂联合卡培他滨(XELOX)方案治疗根治术后胃癌的疗效和安全性。方法:回顾性分析2004年5月-2009年10月北京协和医院肿瘤内科收治的使用XELOX作为胃癌根治术后辅助化疗方案的患者。化疗方案:奥沙利铂静滴2 h,d 1给药;卡培他滨每日2次口服,d 1~14给药;每3周重复,共6个周期。按RECIST标准评价疗效,按NCI-CTC标准评价不良反应。结果:共34例患者,Ⅱ期9例,Ⅲa期10例,Ⅲb期10例,无远处转移的Ⅳ期(M0)5例。共完成162周期化疗,中位5.0周期(2~6周期)。1年,2年,3年生存率分别为85.2%,76.2%和61.9%。主要不良反应为血液学毒性、消化道反应、周围神经感觉障碍和手足综合征,多为1~2度,3~4度不良反应主要有粒细胞减少(11.8%)、血小板减少(8.8%)、恶心(8.8%)、腹泻(5.9%)。结论:XELOX方案辅助治疗手术切除后胃癌安全有效,不良反应易处理。
Objective: To study the efficacy and safety of oxaliplatin combined with capecitabine (XELOX) in the treatment of radical postoperative gastric cancer. METHODS: Retrospective analysis was performed on patients treated with XELOX as adjuvant chemotherapy for radical gastrectomy in Department of Oncology, Peking Union Medical College Hospital between May 2004 and October 2009. Chemotherapy regimen: oxaliplatin intravenous infusion for 2 h, d 1 administration; capecitabine oral administration twice daily, d 1-14 administration; repeated every 3 weeks for a total of 6 cycles. The efficacy was evaluated according to RECIST criteria and adverse reactions were evaluated according to NCI-CTC criteria. RESULTS: A total of 34 patients were included, 9 in stage II, 10 in stage IIIa, 10 in stage IIIb, and 5 in stage IV (M0) with no distant metastasis. A total of 162 cycles of chemotherapy were completed, with a median of 5.0 cycles (2 to 6 cycles). The 1-year, 2-year, 3-year survival rates were 85.2%, 76.2%, and 61.9%, respectively. The main adverse reactions were hematologic toxicity, gastrointestinal reactions, peripheral neurosensory disorders, and hand-foot syndrome, mostly 1 to 2 degrees. The major adverse reactions at 3 to 4 degrees were neutropenia (11.8%) and thrombocytopenia (8.8%). Nausea (8.8%), diarrhea (5.9%). Conclusion: The XELOX regimen is a safe and effective treatment for gastric cancer after surgical resection, and the adverse reactions are easy to deal with.